OWKIN/IDORSIA
23.5.2024 09:01:30 CEST | Business Wire | Press release
Owkin, the first end-to-end TechBio unicorn that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, has unveiled an innovative drug pipeline in oncology and immunology following an exclusive global licensing agreement with Idorsia (SIX: IDIA) to develop and commercialize OKN4395, a clinic-ready best-in-class dual inhibitor of prostanoid receptors EP2 and EP4.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523897876/en/
Unveiling Owkin’s AI precision pipeline
Owkin’s unique pipeline is the product of several internal AI engines powered by multimodal patient data from a network of 61 leading research centers and cutting-edge AI from a team of 110 data scientists that have published 57 top publications. Owkin’s pipeline is differentiated by the use of spatial multiomics data via MOSAIC, the world's largest spatial multiomics dataset in oncology that enables Owkin to capture the tumor microenvironment in a way that few others can. With deep immune response expertise in T-cell connectivity and seven years of successful AI drug discovery projects internally and with leading pharma partners, Owkin is poised to tackle some of the most critical challenges in precision medicine.
OKN4395 is the result of 10 years of drug discovery by experts at Idorsia and external collaborators. Owkin believes this asset has the potential to be a best-in-class dual inhibitor of the very challenging EP2 and EP4 targets thanks to years of medicinal chemistry, a feat that Generative AI has yet to achieve.
Thomas Clozel, MD, CEO & Co-founder: “Our AI-powered precision pipeline demonstrates our dedication to tailoring treatments to specific patient subgroups by using causal biomarkers from patient data. This is how Owkin is driving a paradigm shift in precision health. As a physician, I am proud that we can now extend our pipeline from AI-target discovery and lab validation to clinical trials, getting closer to the ground truth of biology and providing clinical benefits to patients sooner.”
Owkin’s AI Engines select OKN4395 for in-licensing
Owkin’s biomarker engine used multimodal patient data to create detailed signatures of EP2/EP4 biology, combining histology and molecular profiles. This helped identify actionable biomarkers for indication selection and clinical trial development.
Owkin’s AI drug positioning engine then screened over 30 cancer indications for OKN4395, ranking them based on their relevance to the EP2/EP4 pathway. This data-driven process, validated by medical experts, identified the most promising therapeutic combinations for clinical trial success, synergising with traditional expert-driven approaches.
Vassili Soumelis, MD, PhD, Owkin Chief Medical Officer: “Our AI engines integrated rich multimodal patient data from multiple cancer indications, allowing us to discover that EP2/EP4 biology significantly perturbs T cell connectivity within the tumor microenvironment (TME) through direct and indirect mechanisms.”
To de-risk OKN4395’s clinical trial, Owkin will apply AI to build an external control arm in phase 1B and use multimodal patient data to select optimal inclusion/exclusion criteria and prognostic covariates to strengthen the treatment signal in a data-driven way.
Andrew J. Pierce, PhD, SVP Discovery & Development: “As a result of extensive in-house medical chemistry expertise, Idorsia had a very potent dual inhibitor of EP2/EP4, which came with a compelling preclinical dataset including restoration of T cell functionality. With this best-in-class asset, Owkin can now unleash its capacity to decipher complex biology to get us one step closer to finding the right treatment for every patient.”
Leveraging world-leading data access and cutting-edge technologies, Owkin’s pipeline promises a unique approach to tackle some of the most critical challenges in precision medicine. To expand its pipeline further, Owkin intends to harness its AI engines to supplement in-house drug discovery with in-licensed assets in oncology, immunology, and inflammation.
About Owkin
Owkin is the first end-to-end TechBio unicorn on a mission to understand complex biology and derive new multimodal biomarkers through AI. We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing federated technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular disease, immunity and inflammation. Owkin also founded MOSAIC, the world’s largest spatial multiomics atlas for cancer research. Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like Fidelity, GV and Bpifrance, among others.
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 25-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe and North America – the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 750 highly qualified specialists dedicated to realizing our ambitious targets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523897876/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infobip Expands Relationship With Anthropic With Verified Claude Connector for Global Messaging17.11.2026 10:00:00 CET | Press release
New integration enables Claude users to send and track messages across SMS, RCS, MMS and Viber through Infobip. Global AI-first cloud communications platform Infobip has expanded its collaboration with Anthropic with the launch of the Infobip Message connector in the Claude Marketplace. The Anthropic-verified connector enables developers, enterprises and builders using Claude to add global messaging capabilities to AI agents without building separate integrations for individual communication channels. The integration connects Claude with Infobip’s global communications infrastructure, enabling AI agents to send messages across SMS, RCS, MMS and Viber through a single connector. Using Infobip’s send and check status tools, agents can trigger outbound messages and track their delivery status, allowing them to incorporate real-world communication into automated workflows. For businesses building agentic AI applications, the connector can support use cases such as order confirmations, deli
Luminor Partners With Plumery to Accelerate Delivery of Digital Banking Solutions17.11.2026 09:55:00 CET | Press release
Luminor has partnered with financial technology company Plumery, using its headless digital platform to accelerate the delivery of selected digital banking solutions across Estonia, Latvia and Lithuania. Plumery was selected because its technology and approach align well with Luminor’s strategy. The cooperation forms part of Luminor’s broader work to modernise its technology, simplify its products and strengthen its digital channels. Under the partnership, Luminor uses Plumery’s headless, API-first architecture to design and deliver digital banking experiences in combination with the bank’s own applications, customer journeys and integrations. This allows Luminor to develop and introduce new functionality more efficiently, while retaining control over how its digital services are designed and integrated. Luminor Bloom, hosted on Luminor’s new cloud-based banking platform, is the first solution delivered through the partnership. Plumery provides the digital banking interface used for Lu
Oasis Networks Selects PacketLight for Burstable Wavelength Services17.11.2026 09:35:00 CET | Press release
PacketLight Networks, a provider of DWDM and OTN optical transport solutions, today announced that Oasis Networks has selected its 800G transport and OLS optical amplification platforms to support the development of burstable wavelength services in Portugal. PacketLight’s open transport architecture supports Oasis’ plans to allocate optical capacity through software as customer requirements change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117351242/en/ PacketLight’s 800G DWDM transport and OLS optical amplification support Oasis Networks’ Lisbon–Sines connection and the development of burstable wavelength services. The connection between Lisbon and Sines is now in place, with the Sines endpoint at Start Campus. A proof of concept on Oasis’ operational network demonstrated software-controlled optical path establishment and reconfiguration. PacketLight has also completed the design for future site interconnects around
Abu Dhabi International Boat Show Opens This Week With World Premieres and Record Participation17.11.2026 09:27:00 CET | Press release
Held under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region, the Abu Dhabi International Boat Show (ADIBS) returns from 19 to 22 November 2026 at ADNEC Marina Hall for its eighth and largest edition yet, bringing together 1,210 exhibitors and brands from 57 countries, a 13% increase on 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116669938/en/ ADNEC Marina Hall - ADNEC Group, Abu Dhabi – United Arab Emirates (Photo: AETOSWire) Organised by ADNEC Group under the theme “Life on and Beyond the Water”, the show spans more than 96,000 square metres and will feature 168 boats on display in the marina. Additionally, luxury yachts, houseboats, leisure boats and marine sports equipment will be launched for the first time in the region. “This year’s edition is set to be the largest in the Show’s history, with strong growth across key performance indicators reflectin
Lakestar and Rochefort Asset Management Co-Lead Series A for Tiberius Aerospace at over $1 Billion Valuation17.11.2026 09:00:00 CET | Press release
Financing will accelerate production of long-range precision munitions and expand allied sovereign manufacturing capacity. Lakestar, a European technology investment firm and Rochefort Asset Management (Rochefort), a U.S. national security-focused investment firm licensed under the U.S. Department of War's Office of Strategic Capital (OSC) and the Small Business Administration (SBA), today jointly announced that they have co-led an $85 million Series A financing round for defense technology company Tiberius Aerospace, Inc. (Tiberius). The investment values Tiberius at more than $1 billion on a post-money basis making it the latest defense technology unicorn. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117903633/en/ Tiberius Aerospace becomes a defense tech unicorn The round attracted new investors including Dream Ventures and Aero X Ventures, alongside other institutional investors, with participation from existing inv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
